A phase II evaluation of cisplatin in unresectable diffuse malignant mesothelioma: A Southwest Oncology Group Study
| Autor: | Bernard L. Zidar, H. I. Pierce, Stephanie Green, Stanley P. Balcerzak, Liboria Militello, Ralph W. Roach |
|---|---|
| Rok vydání: | 1988 |
| Předmět: |
Adult
Male Mesothelioma Oncology medicine.medical_specialty medicine.medical_treatment Internal medicine Southwestern United States medicine Humans Pharmacology (medical) Aged Pharmacology Cisplatin Chemotherapy Group study business.industry Middle Aged Diffuse malignant mesothelioma medicine.disease Toxicity Drug Evaluation Female Response Duration business Median survival medicine.drug |
| Zdroj: | Investigational New Drugs. 6:223-226 |
| ISSN: | 1573-0646 0167-6997 |
| Popis: | Cisplatin was given intravenously to 35 evaluable patients with unresectable malignant mesothelioma on Southwest Oncology Group (SWOG) Study 8418. Five patients (14.3%) achieved partial response with median response duration of six months (range 2-12 months); eleven patients (31.4%) had stable disease of median duration of 5.5. months (range 2-21 months). Median survival for all patients was 7.5 months, 9 months for responders. Toxicity was as expected except that 12 patients (34.2%) discontinued cisplatin because of side effects. Cisplatin has moderate activity in mesothelioma and further studies with platinum analogues should be pursued. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink